Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treatment with Tibsovo & Voranigo

from pharmaphorum Podcast · host pharmaphorum

At ASCO 2025, Servier presented data in the IDH-mutated cancer space. Onsite at McCormick Place in Chicago, pharmaphorum web editor Nicole Raleigh spoke with Becky Martin, chief US medical at Servier about the key data from the company’s Tibsovo and Voranigo programmes, as well as the implications for patients and the wider themes of the Congress this year. Listen to this and other interviews from ASCO 2025 here.

Episode metadata supplied by the publisher feed · Published Jun 5, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treatment with Tibsovo & Voranigo

0:00 9:25

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of pharmaphorum Podcast?

This episode is 9 minutes long.

When was this pharmaphorum Podcast episode published?

This episode was published on June 5, 2025.

Can I download this pharmaphorum Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!